BeiGene Ltd. (ONC)
NASDAQ: ONC
· Real-Time Price · USD
245.73
-0.95 (-0.39%)
At close: May 30, 2025, 3:59 PM
245.58
-0.06%
After-hours: May 30, 2025, 04:04 PM EDT
-0.39% (1D)
| Bid | 244.55 |
| Market Cap | 1.88B |
| Revenue (ttm) | 4.18B |
| Net Income (ttm) | -392.37M |
| EPS (ttm) | -3.63 |
| PE Ratio (ttm) | -67.69 |
| Forward PE | 37.86 |
| Analyst | Buy |
| Ask | 246.62 |
| Volume | 387,725 |
| Avg. Volume (20D) | 485,358 |
| Open | 248.00 |
| Previous Close | 246.68 |
| Day's Range | 240.40 - 247.19 |
| 52-Week Range | 141.31 - 287.88 |
| Beta | 0.35 |
Analyst Forecast
According to 0 analyst ratings, the average rating for ONC stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 weeks ago
-3.93%
BeiGene shares are trading lower after the company...
Unlock content with
Pro Subscription
1 month ago
+0.96%
BioGene shares are trading higher. Guggenheim reiterated a Buy rating on the stock.
2 weeks ago · businesswire.com
BeiGene to Present at the RBC Capital Markets Global Healthcare ConferenceSAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announc...
3 weeks ago · seekingalpha.com
BeiGene, Ltd., Soon To Be BeOne Medicines: New Name And New ProfitBeiGene, Ltd., soon to be BeOne Medicines, is a global oncology company with a strong focus on innovative cancer treatments, particularly Brukinsa and Tevimbra. Brukinsa, a BTK inhibitor, has shown im...
3 weeks ago · seekingalpha.com
BeiGene, Ltd. (ONC) Q1 2025 Earnings Call TranscriptBeiGene, Ltd.
